<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="861">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02087865</url>
  </required_header>
  <id_info>
    <org_study_id>14-227</org_study_id>
    <nct_id>NCT02087865</nct_id>
  </id_info>
  <brief_title>Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease</brief_title>
  <official_title>Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the sensitivity of functional MRI to detect brain changes caused by&#xD;
      donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for&#xD;
      Alzheimer's Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 24-week study will examine the sensitivity of functional MRI to detect brain changes&#xD;
      caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk&#xD;
      for Alzheimer's Disease. Participants with a family history of Alzheimer's Disease will be&#xD;
      eligible for this study. Participants without a family history of AD will also be enrolled to&#xD;
      serve as a control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BOLD response during functional magnetic resonance imaging</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline to 6 month follow-up fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing scores</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in neuropsychological testing scores from baseline to 6 month follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Genetic Risk for Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants without a family history of AD will undergo the study evaluations but will not receive any study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil HCL</intervention_name>
    <arm_group_label>Donepezil HCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal general cognitive function&#xD;
&#xD;
          -  High Risk Group Only: Family history (1st degree relative) of AD&#xD;
&#xD;
          -  Low Risk Group Only: No family history (1st or 2nd degree relative) of AD&#xD;
&#xD;
          -  Visual and auditory acuity adequate for neuropsychological testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or past history of&#xD;
&#xD;
          -  neurological illnesses/conditions&#xD;
&#xD;
          -  head trauma with significant loss of consciousness&#xD;
&#xD;
          -  medical illnesses/conditions that may affect brain function&#xD;
&#xD;
          -  severe psychiatric disorder&#xD;
&#xD;
          -  substance abuse&#xD;
&#xD;
          -  unstable or severe cardiovascular disease or asthmatic condition&#xD;
&#xD;
          -  history of stroke or transient ischemic attack&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Rao, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Center for Brain Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>May 16, 2022</last_update_submitted>
  <last_update_submitted_qc>May 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

